1.
Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis
by GÓMEZ‐DOMINGUEZ, E.
Alimentary pharmacology & therapeutics, 2008, Vol.27 (5), p.441-447
2.
Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis
by Shirabe, Ken
Journal of gastroenterology, 2018, Vol.53 (7), p.819-826
3.
Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease
by Abe, Masanori
Journal of gastroenterology, 2014, Vol.50 (7), p.776-784
4.
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
by Fedchuk, L.
Alimentary pharmacology & therapeutics, 2014, Vol.40 (10), p.1209-1222
5.
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
by Kim, Gi-Ae
Gut, 2014, Vol.63 (8), p.1325-1332
6.
Randomised clinical study: GR‐MD‐02, a galectin‐3 inhibitor, vs. placebo in patients having non‐alcoholic steatohepatitis with advanced fibrosis
by Harrison, S. A.
Alimentary pharmacology & therapeutics, 2016, Vol.44 (11-12), p.1183-1198
7.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
by Chayama, Kazuaki
Journal of gastroenterology, 2017, Vol.53 (4), p.557-565
8.
Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study
by Shen, Qiujin, MSc
The lancet oncology, 2012, Vol.13 (8), p.817-826
9.
Liver fibrosis and fatty liver in Asian HIV‐infected patients
by Lui, G.
Alimentary pharmacology & therapeutics, 2016, Vol.44 (4), p.411-421
10.
Acute kidney injury in decompensated cirrhosis
by Tsien, Cynthia D
Gut, 2013, Vol.62 (1), p.131-137
11.
Adipokines and cytokines in non‐alcoholic fatty liver disease
by JARRAR, M. H.
Alimentary pharmacology & therapeutics, 2008, Vol.27 (5), p.412-421
12.
Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension
by La Mura, Vincenzo
Gut, 2011, Vol.60 (8), p.1133-1138
13.
Systematic review with meta‐analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance
by Liu, F.
Alimentary pharmacology & therapeutics, 2016, Vol.43 (12), p.1253-1261
14.
A Comparison of Measured and Calculated Free 25(OH) Vitamin D Levels in Clinical Populations
by Schwartz, J. B
The journal of clinical endocrinology and metabolism, 2014, Vol.99 (5), p.1631-1637
15.
Systematic review with meta‐analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B
by Houot, M.
Alimentary pharmacology & therapeutics, 2016, Vol.43 (1), p.16-29
16.
MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation
by Londoño, Maria-Carlota
Gut, 2007, Vol.56 (9), p.1283-1290
17.
Ammonia and amino acid profiles in liver cirrhosis: Effects of variables leading to hepatic encephalopathy
by Holecek, Milan, M.D
Nutrition (Burbank, Los Angeles County, Calif.), 2015, Vol.31 (1), p.14-20
18.
Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis
by Grønbæk, H.
Alimentary pharmacology & therapeutics, 2012, Vol.36 (2), p.173-180
19.
Liver injury is associated with mortality in sickle cell disease
by Feld, J. J.
Alimentary pharmacology & therapeutics, 2015, Vol.42 (7), p.912-921
20.
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
by Yoneda, Masato
Journal of gastroenterology, 2007, Vol.42 (7), p.573-582
